Skip to content

Evaluation of Cardiac Affections in Patients With Mucopolysaccharidosis (MPS) in Assuit University Children Hospital (AUCH)

Evaluation of Cardiac Affections in Patients With Mucopolysaccharidosis (MPS) in Assuit University Children Hospital (AUCH)

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04637646
Acronym
MPS
Enrollment
25
Registered
2020-11-20
Start date
2020-12-01
Completion date
2022-01-29
Last updated
2020-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mucopolysaccharidoses

Brief summary

This study aims to evaluate the different cardiac changes in the various types of MPS disorder and define the outcome of these cardiac abnormalities in those patients admitted to assuit University Children Hospital

Detailed description

The mucopolysaccharidoses (MPSs) are inherited lysosomal storage disorders caused by the absence of functional enzymes that contribute to the degradation of glycosaminoglycans (GAGs). The progressive systemic deposition of GAGs results in multi-organ system dysfunction that varies with the particular GAG deposited and the specific enzyme mutation(s) present. Cardiac involvement has been reported in all MPS syndromes and is a common and early feature, particularly for those with MPS I, II, and VI. Cardiac valve thickening, dysfunction (more severe for left-sided than for right-sided valves), and hypertrophy are commonly present; conduction abnormalities, coronary artery and other vascular involvement may also occur. Cardiac disease emerges silently and contributes significantly to early mortality. The clinical examination of individuals with MPS is often difficult due to physical and, sometimes, intellectual patient limitations. The absence of precordial murmurs does not exclude the presence of cardiac disease. Echocardiography and electrocardiography are key diagnostic techniques for evaluation of valves, ventricular dimensions and function.

Interventions

None listed

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
1 Days to 18 Years

Inclusion criteria

\- All the patients at any age up to 18 years with any type of MPS confirmed by the enzymatic assay

Exclusion criteria

* any patient other than MPS

Design outcomes

Primary

MeasureTime frameDescription
Rate of Cardiac affection in patients with MPSon enrollmentcardiac affection in MPS patients

Contacts

Primary Contacthager mohamed rageh, MBChB
hagerdardiry@gmail.com01065007569
Backup ContactMohamed Mahrous Sayed El-Talawy, PhD
ohamed.mohamed51@med.au.edu.eg01003486596

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026